Cai Jing Wang·2025-12-15 10:20Core Viewpoint - WuXi AppTec announced the completion of a transaction involving the sale of 100% equity in two subsidiaries for a total consideration of 2.8 billion yuan, which is expected to generate a net profit of approximately 960 million yuan, representing over 10% of the company's audited net profit for the fiscal year 2024 [1] Group 1 - The company’s wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., transferred its holdings in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. [1] - The first payment of 1.54 billion yuan has been received from the acquirers, and the transaction has been completed with the target companies no longer included in the company’s consolidated financial statements [1] - The transaction is subject to the fulfillment of various agreements outlined in the equity transfer agreement by all parties involved [1]